Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Hytrin was a prescription terazosin product used for symptomatic benign prostatic hyperplasia and hypertension. FDA lists Hytrin tablets and capsules as discontinued products, while terazosin remains available in current generic products. Terazosin is an alpha-1-selective adrenergic blocker.
read more about what was hytrin ...Terazosin blocks alpha-1 adrenergic receptors. In blood vessels, this relaxes vascular smooth muscle and lowers peripheral resistance. In benign prostatic hyperplasia, it relaxes smooth muscle in the prostate and bladder outlet, which can increase urinary flow and reduce urinary symptoms without shrinking the prostate.
Hytrin labeling covered symptomatic benign prostatic hyperplasia and hypertension. Current generic terazosin carries the same two core indications. Terazosin can be used alone or with other antihypertensive medicines for high blood pressure.
Both benign prostatic hyperplasia and hypertension start at 1 mg at bedtime. Benign prostatic hyperplasia dosing is increased stepwise to 2 mg, 5 mg, or 10 mg once daily according to response. Hypertension commonly uses 1 mg to 5 mg once daily, with selected patients receiving up to 20 mg daily.
Terazosin can cause marked low blood pressure, postural hypotension, and fainting after the first dose, during early treatment, after rapid dose increases, or after restarting therapy. Other concerns include dizziness, drowsiness, priapism, and intraoperative floppy iris syndrome during cataract surgery.
Hytrin contained terazosin, an alpha-1-selective adrenergic blocker.
No. FDA lists Hytrin tablets and capsules as discontinued products, while generic terazosin remains marketed.
The starting dose for benign prostatic hyperplasia or hypertension is 1 mg at bedtime.
The 1 mg bedtime start reduces the risk of severe first-dose hypotension and fainting.
Approved Drug Products with Therapeutic Equivalence Evaluations 46th Edition. U.S. Food and Drug Administration. https://www.fda.gov/downloads/drugs/developmentapprovalprocess/UCM071436.pdf. Date Accessed October 1, 2026.
DailyMed - TERAZOSIN capsule. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57125b47-2156-181c-e063-6394a90ad763. Date Accessed October 1, 2026.
Terazosin. MedlinePlus. https://medlineplus.gov/druginfo/meds/a693046.html. Date Accessed October 1, 2026.
Terazosin. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK545208/. Date Accessed October 1, 2026.
Terazosin Hydrochloride. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Terazosin-Hydrochloride. Date Accessed October 1, 2026.